

CNS drugs are 45% less likely to progress from Phase 3 to regulatory filing than non-CNS drugs*

CNS Research

Time for a paradigm shift

ICON offers solutions that combine in-house expertise and proprietary innovative technology to overcome this challenge

- Imaging and laboratory biomarkers to enrich the study population
- Advice and implementation of innovative "wearable" endpoints
- Centralised and web based endpoint assessment to minimise inter-rater variability
- Advanced data analytics with ICONIK, to improve data reliability and minimise placebo-response
- Design, simulation and execution of adaptive trials to improve decision making at critical milestones
  - ADDPLAN software validated and used by regulatory agencies around the world

Contact us today
Enquiries@iconplc.com

ICONplc.com/CNS

*(Nat-Rev-Drug Discov 14, 2015)